S0077 Clindamycin Injection HCPCS Reimbursement

HCPCS Level II code S0077 denotes the injection of clindamycin phosphate, 300 mg, a parenteral antibiotic administration commonly used in ambulatory and outpatient settings. Nationally, this code matters for accurate reporting of administered anti-infective therapy across clinics, physician offices, and hospital outpatient departments, and it affects claims processing, utilization tracking, and clinical documentation for antibiotic administration.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and payer coverage landscape. The publication outlines common billing considerations, allowed service lines, and where this code fits in clinical workflows for parenteral antibiotic therapy.

The report provides benchmarks and operational guidance relevant to billing and coding teams, revenue cycle managers, and clinical staff involved in medication administration. It also highlights billing modifiers commonly applied to similar administration services and notes where data was not available in the input. The goal is to give a clear, national-level picture of how HCPCS Level II code S0077 is used and reimbursed across major payers.

Billing Code Overview

HCPCS Level II code S0077 represents an injection of clindamycin phosphate, 300 mg. This service is primarily a medication administration procedure involving the intramuscular or intravenous delivery of a 300 mg dose of clindamycin phosphate.

Typical site of service for this HCPCS Level II code includes outpatient clinics, physician offices, hospital outpatient departments, and other ambulatory care settings where parenteral antibiotic administration is performed.

Clinical Context

A typical patient is an adult with a confirmed or suspected skin and soft tissue infection (such as cellulitis or abscess) or a postoperative wound infection who requires parenteral antibiotic therapy. The patient presents to an outpatient infusion center, emergency department, ambulatory surgical center, or inpatient ward and is evaluated by a physician or advanced practice clinician. After assessment and indication for parenteral clindamycin, the medication S0077 (Injection, clindamycin phosphate, 300 mg) is prepared by pharmacy or nursing, administered via intramuscular or intravenous route per facility protocol, and documented in the medication administration record. Vital signs, allergy verification, informed consent for injectable therapy, and observation for immediate adverse reaction (including hypersensitivity and Clostridioides difficile risk counseling) are completed. Typical workflow steps include orders entry, medication preparation, administration with route/lot number documented, monitoring for adverse effects, and follow-up instructions for additional doses or transition to oral therapy based on clinical response and culture results.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when administration required substantially greater resources (extensive monitoring or complex access) than typical for an injection service.

Taxonomy Code	Specialty	Notes
`208000000X`	Family Medicine	Commonly orders and administers parenteral antibiotics in outpatient and urgent care settings.
`208000000S`	Internal Medicine	Manages inpatient and outpatient infectious conditions requiring `S0077`.
`213E00000X`	Emergency Medicine	Frequently administers parenteral clindamycin for acute infections in the ED.
`363L00000X`	Infectious Disease	Consults on antibiotic selection and duration for complex infections.
`207P00000X`	Anesthesiology	Involved when sedation or anesthesia is required for procedure-related injections (rare).

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L03.90`	Cellulitis, unspecified	Cellulitis commonly requires parenteral antibiotics like clindamycin when severe or in patients unable to tolerate oral therapy.
`L02.91`	Cutaneous abscess of unspecified site	Abscesses often require incision and drainage plus parenteral antibiotics for moderate to severe infections.
`T81.4XXA`	Infection following a procedure, initial encounter	Postoperative wound infections may prompt use of parenteral clindamycin for gram-positive coverage.
`A49.02`	Methicillin resistant Staphylococcus aureus infection, unspecified site	MRSA infections are frequently treated with clindamycin when susceptibility is documented.
`K65.9`	Peritonitis, unspecified	Intra-abdominal infections with anaerobic components may be treated with clindamycin as part of regimen.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (single or initial substance/drug)	Commonly used for billing the professional component of a single injectable antibiotic administration in an outpatient setting alongside `S0077`.
`96374`	Therapeutic, prophylactic, or diagnostic injection requiring prolonged infusion and monitoring	Used when administration requires extended infusion time and continuous monitoring beyond a standard bolus injection.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Often billed on the same day for clinical evaluation that supports the decision to administer parenteral clindamycin.
`36415`	Collection of venous blood by venipuncture	Commonly performed before or after administration for culture collection or therapeutic monitoring.
`10160`	Incision and drainage of abscess; simple	Performed when source control (I&D) is required and parenteral `S0077` is administered as adjunctive therapy.

OpenPayer

Summary & Overview

HCPCS S0077: Injection, Clindamycin Phosphate 300 mg